DoD Breast Cancer, Clinical Research Extension Award | HT942525BCRPCREA2

Opportunity Information: Apply for HT942525BCRPCREA2

The FY25 DoD Breast Cancer Research Program (BCRP) Clinical Research Extension Award is a discretionary grant opportunity from the Department of the Army (USAMRAA) designed to extend or expand ongoing or previously conducted breast cancer clinical studies. The core purpose is to get more clinically meaningful value from patients participation in clinical research by supporting additional data collection, longer follow-up, and deeper analysis when earlier plans fell short. This mechanism specifically targets situations where important insights may have been left on the table because a trial ended early, participants were not followed long enough to capture key outcomes, or biospecimens and other data were not collected, curated, or analyzed as fully as needed.

The work proposed must connect to at least one of the FY25 BCRP overarching challenges, unless the applicant provides a strong justification for why an exception is appropriate. In practical terms, applicants should be prepared to show how the extension effort will address a defined breast cancer problem and how the added follow-up or additional analyses will change what the field can conclude from an existing clinical study. The emphasis is on clinically relevant impact rather than starting an entirely new clinical trial from scratch; the award is meant to build on prior participant contributions and recover or enhance knowledge that would otherwise be lost.

A defining requirement of this award is meaningful consumer advocacy involvement: the research team must include two or more breast cancer consumer advocates. These advocates are expected to contribute patient-centered perspective to the planning and conduct of the proposed extension work, helping ensure that the questions being answered and the outcomes being prioritized align with patient needs and real-world decision-making. This requirement signals that the program values not only scientific rigor, but also relevance, transparency, and accountability to the breast cancer community.

The funding structure allows either a single Principal Investigator (PI) or a two-PI partnership model. Under the Partnering PI Option, the two leaders are designated as an Initiating PI and a Partnering PI. The submission process is staged: only the Initiating PI submits the pre-application, but both the Initiating and Partnering PIs must submit applications at the full application stage. The program is strict about administrative completeness here: proposals can be withdrawn if both applications are not submitted by the full deadline, or if either the initiating or partnering submission is administratively withdrawn, which effectively makes the partnership incomplete.

Administratively, the opportunity is listed as Funding Opportunity Number HT942525BCRPCREA2 under CFDA 12.420, categorized under Science and Technology and other Research and Development. Eligibility is listed as unrestricted, meaning the program does not limit applicants to a narrow set of institution types in the posted summary. The original closing date is September 10, 2025, and the posting indicates an expectation of one award. While an award ceiling is referenced in the listing, the specific maximum amount is not provided in the text shared, so applicants would need to confirm budget limits and any cost rules in the full announcement package.

Overall, this award is best understood as a mechanism for maximizing the return on existing clinical research investments in breast cancer, especially where additional follow-up time, improved data completeness, or more robust analyses could unlock findings that better inform patient care, survivorship considerations, recurrence risk, long-term safety, or other clinically important endpoints. The program places equal weight on extending the scientific usefulness of prior trials and ensuring the work remains grounded in patient priorities through required consumer advocate participation.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Clinical Research Extension Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2025-06-16.
• Applicants must submit their applications by 2025-09-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942525BCRPCREA2

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: